These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8368758)

  • 1. Randomized study of adjuvant immunotherapy with autologous tumor cells and BCG in renal cancer.
    Galligioni E; Francini M; Quaia M; Carbone A; Spada A; Sacco C; Favaro D; Santarosa M; Carmignani G; Di Donna D
    Ann N Y Acad Sci; 1993 Aug; 690():367-9. PubMed ID: 8368758
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study.
    Galligioni E; Quaia M; Merlo A; Carbone A; Spada A; Favaro D; Santarosa M; Sacco C; Talamini R
    Cancer; 1996 Jun; 77(12):2560-6. PubMed ID: 8640706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific antitumour vaccine for renal cancer.
    Fishman M; Antonia S
    Lancet; 2004 Feb; 363(9409):583-4. PubMed ID: 14987879
    [No Abstract]   [Full Text] [Related]  

  • 4. [Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization].
    Pomer S; Thiele R; Staehler G; Drehmer I; Löhrke H; Schirrmacher V
    Urologe A; 1995 May; 34(3):215-20. PubMed ID: 7610516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
    Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects.
    Adler A; Gillon G; Lurie H; Shaham J; Loven D; Shachter Y; Shani A; Servadio C; Stein JA
    J Biol Response Mod; 1987 Dec; 6(6):610-24. PubMed ID: 3330126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tumor cell vaccination for treatment of renal cell carcinoma].
    Kriegmair M; Oberneder R
    Urologe A; 1995 May; 34(3):204-7. PubMed ID: 7610513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy of metastatic renal cell cancer].
    Manseck A; Wirth M
    Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.
    Jocham D; Richter A; Hoffmann L; Iwig K; Fahlenkamp D; Zakrzewski G; Schmitt E; Dannenberg T; Lehmacher W; von Wietersheim J; Doehn C
    Lancet; 2004 Feb; 363(9409):594-9. PubMed ID: 14987883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma.
    Dillman R; Barth N; Vandermolen L; Mahdavi K; Beutel L; de Leon C; DePriest C; Nayak S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):570-80. PubMed ID: 15650449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the specific delayed cutaneous hypersensitivity response(DTCH) after specific active immunotherapy (SAI) using autologous tumor cells in patients operated upon for renal carcinoma].
    Francini M; Galligioni E; Carbone A; Trovò MG; Di Donna D; Merlo A; Dal Bo V; Quaia M; Spada A; Crivellari D
    Arch Ital Urol Androl; 1993 Apr; 65(2):185-8. PubMed ID: 8330066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active specific immunotherapy with an autologous virus-modified tumour cell vaccine in human renal cell carcinoma (RCC).
    Hinkel A; de Riese W; Alefelder J; Laumann D; Falkenberg FW; Senge T; Hertle L
    Eur J Cancer; 1995 Sep; 31A(10):1719-20. PubMed ID: 7488436
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
    Bellmunt J; Ribas A
    Eur Urol; 2009 Jun; 55(6):1342-3. PubMed ID: 19201525
    [No Abstract]   [Full Text] [Related]  

  • 15. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells.
    McCune CS; O'Donnell RW; Marquis DM; Sahasrabudhe DM
    Cancer Immunol Immunother; 1990; 32(1):62-6. PubMed ID: 2289200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Systemic treatment of renal-cell carcinoma--present status].
    Steiner T; Schubert J
    Dtsch Med Wochenschr; 2001 Sep; 126(39):1080-4. PubMed ID: 11602916
    [No Abstract]   [Full Text] [Related]  

  • 17. Radio frequency ablation combined with interleukin-2 induces an antitumor immune response to renal cell carcinoma in a murine model.
    Kroeze SG; Daenen LG; Nijkamp MW; Roodhart JM; de Gast GC; Bosch JL; Jans JJ
    J Urol; 2012 Aug; 188(2):607-14. PubMed ID: 22704448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TroVax(®) vaccine therapy for renal cell carcinoma.
    Zhang RT; Bines SD; Ruby C; Kaufman HL
    Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer.
    Dillman RO; Beutel LD; Cornforth AN; Nayak SK
    Cancer Biother Radiopharm; 2000 Apr; 15(2):161-8. PubMed ID: 10803321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy of renal cell carcinoma with active-specific-immunotherapy (ASI) using autologous tumor vaccine.
    Repmann R; Wagner S; Richter A
    Anticancer Res; 1997; 17(4B):2879-82. PubMed ID: 9329553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.